PMID- 28177886
OWN - NLM
STAT- MEDLINE
DCOM- 20180424
LR  - 20220408
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 17
DP  - 2017 Apr 25
TI  - Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for 
      hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and 
      meta-analysis.
PG  - 29416-29427
LID - 10.18632/oncotarget.15075 [doi]
AB  - BACKGROUND: The benefits of transarterial chemoembolization plus sorafenib 
      (TACE-S) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) 
      remain controversial. We compared the effectiveness and safety of TACE-S and TACE 
      for HCC with PVTT. METHODS: The Cochrane Library, PubMed, EMBASE, Chinese 
      National Knowledge Infrastructure, VIP, Wan Fang, and Sino Med databases were 
      systematically searched for studies of HCC with PVTT treated using TACE-S. Two 
      authors independently extracted study outcomes, including overall survival (OS), 
      time to progression (TTP), objective response (tumor response) and adverse events 
      (AEs). RESULTS: Eight high-quality, retrospective studies with 1091 patients 
      (TACE-S=356, TACE=735) were included in the review. Five retrospective studies 
      with 973 patients (TACE-S=238, TACE=735) were included in the meta-analysis. The 
      objective response rate (ORR, OR=3.59, 95% CI=1.74-7.39; I2=21%, P=0.0005 ) and 
      disease control rate (DCR, OR=4.72, 95% CI=1.75-12.72; I2=56%, P=0.002) favored 
      TACE-S. TACE-S significantly increased 6-month OS (OR=3.47; 95% CI=2.47-4.89; 
      I2=0%, P < 0.00001) and 1-year OS (OR=3.10; 95% CI=2.22-4.33; I2=41%, P < 
      0.00001). The hazard ratio (HR) for OS (HR=0.62; 95% CI=0.51-0.75; I2=30%, P < 
      0.00001) also indicated that TACE-S was superior to TACE. TACE-S with PVTT had 
      better outcomes in the first-order portal vein branch and lower-order portal vein 
      branches than in the main portal vein and upper branches to superior mesenteric 
      vein. The most common AEs were hand-foot skin reaction (HFSR, 178; 73%), diarrhea 
      (142; 58%) and alopecia (76; 31%); AEs of grade 3/4 were rare. CONCLUSIONS: 
      TACE-S may improve OS, ORR, TTP and DCR for HCC patients with PVTT compared to 
      TACE.
FAU - Zhang, XiuPing
AU  - Zhang X
AD  - Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second 
      Military Medical University. Shanghai, China.
FAU - Wang, Kang
AU  - Wang K
AD  - Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second 
      Military Medical University. Shanghai, China.
FAU - Wang, Meng
AU  - Wang M
AD  - Department of Medical Statistical, Second Military Medical University, Shanghai, 
      China.
FAU - Yang, Guang
AU  - Yang G
AD  - Company 5 of Student Brigade, Second Military Medical University, Shanghai, 
      China.
FAU - Ye, XiaoFei
AU  - Ye X
AD  - Department of Medical Statistical, Second Military Medical University, Shanghai, 
      China.
FAU - Wu, MengChao
AU  - Wu M
AD  - Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second 
      Military Medical University. Shanghai, China.
FAU - Cheng, ShuQun
AU  - Cheng S
AD  - Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second 
      Military Medical University. Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Phenylurea Compounds)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Hepatocellular/*drug therapy/pathology
MH  - Chemoembolization, Therapeutic/*methods
MH  - Humans
MH  - Liver Neoplasms/*drug therapy/pathology
MH  - Middle Aged
MH  - Niacinamide/administration & dosage/*analogs & 
      derivatives/pharmacology/therapeutic use
MH  - Phenylurea Compounds/administration & dosage/pharmacology/*therapeutic use
MH  - Sorafenib
PMC - PMC5438741
OTO - NOTNLM
OT  - PVTT
OT  - TACE
OT  - combined treatment
OT  - hepatocellular carcinoma
OT  - meta-analysis
OT  - sorafenib
OT  - systematic review
COIS- CONFLICTS OF INTEREST There are no financial disclosures, conflicts of interest, 
      and/or acknowledgements.
EDAT- 2017/02/09 06:00
MHDA- 2018/04/25 06:00
PMCR- 2017/04/25
CRDT- 2017/02/09 06:00
PHST- 2016/11/08 00:00 [received]
PHST- 2017/01/09 00:00 [accepted]
PHST- 2017/02/09 06:00 [pubmed]
PHST- 2018/04/25 06:00 [medline]
PHST- 2017/02/09 06:00 [entrez]
PHST- 2017/04/25 00:00 [pmc-release]
AID - 15075 [pii]
AID - 10.18632/oncotarget.15075 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Apr 25;8(17):29416-29427. doi: 10.18632/oncotarget.15075.